Vaishali Pharma

Why is Vaishali Pharma Ltd falling/rising?

As of 27-Jun, Vaishali Pharma Ltd's stock price is at 7.29, down 0.95%, and has significantly underperformed the sector and benchmark indices. The company's weak long-term fundamentals and consistent underperformance have led to declining investor confidence and a year-to-date decline of 15.43%.

As of 27-Jun, Vaishali Pharma Ltd's stock price is falling, currently at 7.29, reflecting a change of -0.07 or -0.95%. The stock has underperformed the sector today by 0.67%. Over the past week, it has decreased by 4.95%, while the benchmark Sensex has only fallen by 0.46%. Year-to-date, the stock has declined by 15.43%, significantly worse than the Sensex's drop of 7.94%. <BR><BR>Despite some positive indicators, such as a higher profit after tax and a strong return on capital employed, the company is facing challenges that contribute to its declining stock price. The operating losses and weak long-term fundamental strength are significant concerns, with an annual growth rate of only 9.66% in operating profit over the last five years. Additionally, the company's ability to service its debt is weak, as indicated by a poor EBIT to interest ratio of 1.76. <BR><BR>Moreover, the stock has consistently underperformed against the benchmark over the last three years, with a staggering -39.80% return in the past year alone. This consistent underperformance, combined with the company's weak long-term growth prospects, suggests that investors are losing confidence, leading to the current decline in stock price.

Which are the latest news on Vaishali Pharma?

What does Vaishali Pharma do?

Vaishali Pharma Ltd is a micro-cap company in the Pharmaceuticals & Biotechnology industry, incorporated in 2008. As of March 2026, it reported net sales of 27 Cr and a net profit of 0 Cr, with a market cap of INR 95 Cr.

Overview:<BR>Vaishali Pharma Ltd is a micro-cap company operating in the Pharmaceuticals & Biotechnology industry.<BR><BR>History:<BR>Vaishali Pharma Ltd was incorporated in 2008 as a Private Limited Company and later acquired the business of its promoter's proprietorship firm. The latest quarterly results reported net sales and net profit for March 2026.<BR><BR>Financial Snapshot:<BR>- Net Sales: 27 Cr (Quarterly Results - Mar 2026)<BR>- Net Profit: 0 Cr (Quarterly Results - Mar 2026)<BR>- Market-cap: INR 95 Cr (Micro Cap)<BR><BR>Key Metrics:<BR>- P/E: 23.00<BR>- Industry P/E: 34<BR>- Dividend Yield: 0.00%<BR>- Debt-Equity: 0.25<BR>- Return on Equity: 5.84%<BR>- Price to Book: 1.37<BR><BR>Contact Details:<BR>Address: 706 to 709 7th Floor Aravali, Business Centre Borivali(W) Mumbai Maharashtra : 400092<BR>Tel: 91-22-28928833<BR>Email: investor@vaishalipharma.com<BR>Website: http://www.vaishalipharma.com

How big is Vaishali Pharma?

As of 10th June, Vaishali Pharma Ltd has a market capitalization of 95.00 Cr, with recent net sales of 85.03 Cr and a net profit of 2.92 Cr over the last three quarters.

As of 10th June, <BR><BR>Market Cap: Vaishali Pharma Ltd has a market capitalization of 95.00 Cr, categorizing it as a Micro Cap company.<BR><BR>Recent Quarterly Performance: The sum of Net Sales for the latest three quarters is 85.03 Cr, while the sum of Net Profit for the same period is 2.92 Cr.<BR><BR>Balance Sheet Snapshot: The reporting period is for March 2025, with Shareholder's Funds amounting to 64.92 Cr and Total Assets totaling 109.66 Cr.

Who are in the management team of Vaishali Pharma?

The management team of Vaishali Pharma includes Atul Vasani (Chairman & Managing Director), Jagruti Vasani (Whole-time Director), Dewansh Vasani (Executive Director), and several Independent Directors: Ashvin Jamnadas Ganatra, Manish Bhagwandas Ved, and Pratik Vikram Jakhelia, along with Vishwa Mekhia (Company Secretary & Compliance Officer).

The management team of Vaishali Pharma includes the following individuals:<BR><BR>1. **Atul Vasani** - Chairman & Managing Director<BR>2. **Jagruti Vasani** - Whole-time Director<BR>3. **Dewansh Vasani** - Executive Director<BR>4. **Ashvin Jamnadas Ganatra** - Independent Director<BR>5. **Manish Bhagwandas Ved** - Independent Director<BR>6. **Vishwa Mekhia** - Company Secretary & Compliance Officer<BR>7. **Pratik Vikram Jakhelia** - Independent Director<BR><BR>If you need more details about any specific member or their roles, feel free to ask!

Who are the peers of the Vaishali Pharma?

Vaishali Pharma's peers include Sotac Pharma, Onyx Biotec, Pharmaids Pharma, Mercury Labs, Denis Chem Lab, Concord Drugs, Makers Labs, Amwill Health, and Godavari Drugs. Vaishali Pharma shows below-average growth and capital structure, with a 1-year return of -44.12%, the lowest among its peers.

Peers: The peers of Vaishali Pharma are Sotac Pharma., Onyx Biotec, Pharmaids Pharma, Mercury Labs, Denis Chem Lab, Concord Drugs, Makers Labs., Amwill Health, and Godavari Drugs.<BR><BR>Quality Snapshot: Excellent management risk is observed at Denis Chem Lab and Amwill Health, while Average management risk is found at Onyx Biotec and Mercury Labs. Below Average management risk is present at Sotac Pharma., Vaishali Pharma, Pharmaids Pharma, Concord Drugs, Makers Labs., and Godavari Drugs. Growth is Average at Onyx Biotec and Amwill Health, while Below Average growth is noted at Vaishali Pharma, Sotac Pharma., Pharmaids Pharma, Mercury Labs, Concord Drugs, Makers Labs., and Godavari Drugs. Capital Structure is Excellent at Mercury Labs and Denis Chem Lab, Average at Sotac Pharma and Onyx Biotec, and Below Average at Vaishali Pharma, Pharmaids Pharma, Concord Drugs, Makers Labs., Amwill Health, and Godavari Drugs.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Onyx Biotec at -20.00%, while Vaishali Pharma has the lowest at -44.12%, indicating a significantly worse performance compared to its peers. Additionally, the six-month return is negative for Vaishali Pharma, Sotac Pharma., and Godavari Drugs.

Should I buy, sell or hold Vaishali Pharma Ltd?

Are Vaishali Pharma Ltd latest results good or bad?

Vaishali Pharma Ltd's latest Q4 FY26 results are concerning, with a 68.94% drop in net profit and negative operating margins, indicating operational distress and reliance on unsustainable non-operating income. Overall, the performance suggests significant challenges for the company's sustainability.

Vaishali Pharma Ltd's latest results for Q4 FY26 indicate significant challenges for the company. While net sales increased by 9.25% quarter-on-quarter to ₹26.93 crores, the consolidated net profit plummeted by 68.94% to just ₹0.41 crores. This stark decline in profitability raises concerns, especially given that the operating margin turned negative at -0.74%, a drastic fall from a positive margin of 6.33% in the previous quarter.<BR><BR>The company's reliance on non-operating income is alarming, with other income accounting for 700% of profit before tax, suggesting that the reported profitability is not sustainable and heavily dependent on non-core activities. Additionally, the return on equity (ROE) is at 5.98%, which is below the industry average, indicating poor capital efficiency.<BR><BR>Overall, the financial performance reflects operational distress, with negative operating margins and significant volatility in revenue. The combination of these factors suggests that the latest results are not good, and the company faces serious questions regarding its business sustainability moving forward.

How has been the historical performance of Vaishali Pharma?

Vaishali Pharma has experienced fluctuating financial performance, with net sales increasing from INR 52.31 crore in March 2021 to INR 99.03 crore in March 2025, but significant declines in profitability and negative cash flow in March 2025. Despite growth in total assets and a reduction in debt, the company's operating profit margin and profits before and after tax have sharply decreased.

Answer:<BR>The historical performance of Vaishali Pharma shows significant fluctuations in its financial metrics over the years.<BR><BR>Breakdown:<BR>Vaishali Pharma's net sales have shown a steady increase from INR 52.31 crore in March 2021 to INR 99.03 crore in March 2025, with a notable jump from INR 69.66 crore in March 2023 to INR 86.28 crore in March 2024. However, the total operating income peaked at INR 11.35 crore in March 2023 but dropped to INR 3.31 crore by March 2025. The operating profit margin, which was as high as 13.09% in March 2023, fell sharply to 0.1% in March 2025. Profit before tax also declined significantly from INR 8.85 crore in March 2023 to INR 1.23 crore in March 2025, while profit after tax decreased from INR 6.60 crore to INR 0.82 crore in the same period. The company's total assets increased from INR 66.08 crore in March 2020 to INR 109.66 crore in March 2025, reflecting growth in shareholder's funds, which rose to INR 64.92 crore. Despite this growth, total debt decreased from INR 14.72 crore in March 2020 to INR 8.50 crore in March 2025. Cash flow from operating activities has been negative in March 2025 at INR -18.00 crore, contrasting with positive cash flows in previous years. Overall, Vaishali Pharma's financial performance indicates a complex trajectory with growth in sales and assets but challenges in profitability and cash flow management.

Who are the top shareholders of the Vaishali Pharma?

The top shareholders of Vaishali Pharma include Atul Arvindbhai Vasani with 21.1%, and Sapan Anil Shah as the highest public shareholder at 6.82%. Individual investors own 65.24% of the company, with no pledged promoter holdings or mutual funds/foreign institutional investors involved.

The top shareholders of Vaishali Pharma include Atul Arvindbhai Vasani, who holds the largest stake at 21.1%. The highest public shareholder is Sapan Anil Shah, with a holding of 6.82%. Additionally, individual investors collectively own 65.24% of the company. Notably, there are no pledged promoter holdings, and the company does not have any mutual funds or foreign institutional investors holding shares.

Is Vaishali Pharma overvalued or undervalued?

As of February 7, 2025, Vaishali Pharma is considered overvalued and risky, with a high PE ratio of 137.42, a PEG ratio of 9.89, and an EV to EBITDA ratio of 149.40, indicating unfavorable valuation metrics compared to its peers and a stock return of -7.57% versus the Sensex's 7.87%.

As of 7 February 2025, Vaishali Pharma's valuation grade has moved from very expensive to risky, indicating a shift in perception regarding its market position. The company is currently overvalued, as evidenced by its high PE ratio of 137.42 and a PEG ratio of 9.89, which suggests that the stock price is not justified by its earnings growth potential. Additionally, the EV to EBITDA ratio stands at 149.40, highlighting significant concerns about profitability relative to enterprise value.<BR><BR>In comparison to its peers, Vaishali Pharma's valuation metrics appear unfavorable; for instance, its PE ratio is significantly higher than the industry average, suggesting that investors are paying a premium for its shares. Notably, the company has underperformed relative to the Sensex over the past year, with a stock return of -7.57% compared to the Sensex's 7.87%. Given these factors, Vaishali Pharma is positioned as overvalued in the current market landscape.

What is the technical trend for Vaishali Pharma?

As of June 4, 2025, Vaishali Pharma's technical trend is mildly bearish, supported by moving averages and Bollinger Bands, despite a mildly bullish weekly MACD.

As of 4 June 2025, the technical trend for Vaishali Pharma has changed from bearish to mildly bearish. The weekly MACD indicates a mildly bullish stance, while the monthly MACD shows a mildly bearish trend. The Bollinger Bands and moving averages on the weekly and daily time frames are all signaling mildly bearish conditions. The KST is mildly bullish weekly but also mildly bearish monthly, and the Dow Theory reflects a mildly bearish stance on the weekly chart with no trend on the monthly. Overall, the current technical stance is mildly bearish, driven primarily by the moving averages and Bollinger Bands.

When is the next results date for Vaishali Pharma?

No Upcoming Board Meetings

What is the bonus history of the Vaishali Pharma?

Vaishali Pharma has a history of issuing bonus shares, with the most recent being a 1:1 bonus announced for October 15, 2024. Previously, a 3:5 bonus was issued on October 18, 2019.

Vaishali Pharma has a notable bonus history. The most recent bonus issue was announced as a 1:1 bonus, with an ex-date of October 15, 2024. Prior to that, the company issued a bonus in a 3:5 ratio, with the record date on October 18, 2019, and an ex-date of October 17, 2019. This indicates that Vaishali Pharma has actively engaged in rewarding its shareholders through bonus shares in the past.

Has Vaishali Pharma declared dividend?

No Dividend History Available